All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Cook et al. conducted a two-arm, parallel-group, superiority, randomized controlled trial (IMPROVE, ISRCTN 14197181), which enrolled patients with CLL across 11 UK hematology clinics to evaluate the impact on antibody responses of continuous BTKi use vs a 3-week BTKi pause. Findings were published in The Lancet Hematology.1 Eligible patients (N = 99) with a diagnosis of CLL who had been on either ibrutinib or acalabrutinib for at least 12 months were randomized 1:1 to receive continuous BTKi (n = 49) or to have a 3-week pause (n = 50). The primary outcome measure was RBD antibody titers 3 weeks after SARS-CoV-2 booster vaccination. Key secondary outcomes included RBD titers at 12 weeks and safety. |
Key learnings |
At 3 weeks, the geometric mean RBD antibody titer was 218.8 U/mL in the continue group vs 153.4 U/mL in the pause group (GMR 1.104; 95% CI, 0.565–2.158; p = 0.770). |
No difference in RBD antibody titer was observed between the continue group (177.6 U/mL) and the pause group (122.4 U/mL) at 12 weeks (GMR 1.037; 95% CI, 0.529–2.035; p = 0.91). |
At 12 weeks, one participant reported lymphadenopathy in the pause group vs no reports of lymphadenopathy in the continue group. While there were no hospital admissions reported, one participant in the pause group died due to COVID-19 infection. |
This trial found no benefit from pausing BTKi therapy during SARS-CoV-2 booster vaccination in patients with CLL and suggests that a pause should not be recommended to enhance immunity during vaccination in clinical practice. |
BTKi, Bruton’s tyrosine kinase inhibitor; CI, confidence interval; CLL, chronic lymphocytic leukemia; GMR, geometric mean ratio; RBD, receptor binding domain; SARs-CoV-2, severe acute respiratory syndrome coronavirus 2.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?